| 摘要 |
Novel compositions for the treatment of IRDS and ARDS contain at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment with these compositions and the mortality associated with these syndromes can be significantly reduced with the administration of these compositions.
|
